Cargando…
The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217326/ https://www.ncbi.nlm.nih.gov/pubmed/37232838 http://dx.doi.org/10.3390/curroncol30050380 |
| _version_ | 1785048509825679360 |
|---|---|
| author | Trudeau, Maureen Fraser, Brent |
| author_facet | Trudeau, Maureen Fraser, Brent |
| author_sort | Trudeau, Maureen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10217326 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | MDPI |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102173262023-05-27 The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895 Trudeau, Maureen Fraser, Brent Curr Oncol Comment MDPI 2023-05-16 /pmc/articles/PMC10217326/ /pubmed/37232838 http://dx.doi.org/10.3390/curroncol30050380 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Comment Trudeau, Maureen Fraser, Brent The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895 |
| title | The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895 |
| title_full | The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895 |
| title_fullStr | The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895 |
| title_full_unstemmed | The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895 |
| title_short | The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895 |
| title_sort | cadth pcodr expert review committee process explained. comment on rayson et al. access to neoadjuvant pertuzumab for her2 positive breast cancer in canada: a dilemma increasingly difficult to explain. curr. oncol. 2022, 29, 9891–9895 |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217326/ https://www.ncbi.nlm.nih.gov/pubmed/37232838 http://dx.doi.org/10.3390/curroncol30050380 |
| work_keys_str_mv | AT trudeaumaureen thecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplaincurroncol20222998919895 AT fraserbrent thecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplaincurroncol20222998919895 AT trudeaumaureen cadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplaincurroncol20222998919895 AT fraserbrent cadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplaincurroncol20222998919895 |